Kangtai bio subsidiary secures approval for inactivated polio vaccine

Shenzhen Kangtai Biological Products Co., Ltd. announced today that its wholly-owned subsidiary, Beijing Minhai Biotechnology Co., Ltd., has obtained a "Drug Registration Certificate" from the National Medical Products Administration. The certificate is for its Sabin strain inactivated polio vaccine (Vero cell), with approval number S20250051, valid until September 8, 2030. This preventative biological product is administered via injection, with each bottle containing 0.5ml.

This vaccine is designed to prevent acute infectious diseases caused by poliovirus by stimulating immunity against poliovirus types I, II, and III. This approval enriches Kangtai Bio's product pipeline and strengthens its core competitiveness, laying a solid foundation for future development and its market position.

The company advises investors that while the registration certificate has been received, the timing of the product's market launch is uncertain, and caution is warranted regarding investment risks.